MXPA03011825A - Combinacion de ingrediente activo para tratar una dependencia de sustancias aditivas o narcoticas utilizando medicamentos. - Google Patents

Combinacion de ingrediente activo para tratar una dependencia de sustancias aditivas o narcoticas utilizando medicamentos.

Info

Publication number
MXPA03011825A
MXPA03011825A MXPA03011825A MXPA03011825A MXPA03011825A MX PA03011825 A MXPA03011825 A MX PA03011825A MX PA03011825 A MXPA03011825 A MX PA03011825A MX PA03011825 A MXPA03011825 A MX PA03011825A MX PA03011825 A MXPA03011825 A MX PA03011825A
Authority
MX
Mexico
Prior art keywords
treating
narcotics
dependence
active ingredient
medicaments
Prior art date
Application number
MXPA03011825A
Other languages
English (en)
Spanish (es)
Inventor
Opitz Klaus
Original Assignee
Hf Arzneimittelforsch Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hf Arzneimittelforsch Gmbh filed Critical Hf Arzneimittelforsch Gmbh
Publication of MXPA03011825A publication Critical patent/MXPA03011825A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
MXPA03011825A 2001-06-18 2002-06-15 Combinacion de ingrediente activo para tratar una dependencia de sustancias aditivas o narcoticas utilizando medicamentos. MXPA03011825A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10129265A DE10129265A1 (de) 2001-06-18 2001-06-18 Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
PCT/EP2002/006630 WO2002102388A2 (de) 2001-06-18 2002-06-15 Wirkstoffkombination von z.b. galanthamin oder desoxypeganin mit z.b. acamprosat oder memantin gegen sucht wie z.b. alkoholismus

Publications (1)

Publication Number Publication Date
MXPA03011825A true MXPA03011825A (es) 2005-03-07

Family

ID=7688529

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03011825A MXPA03011825A (es) 2001-06-18 2002-06-15 Combinacion de ingrediente activo para tratar una dependencia de sustancias aditivas o narcoticas utilizando medicamentos.

Country Status (27)

Country Link
US (1) US20040192683A1 (enExample)
EP (1) EP1397138B1 (enExample)
JP (1) JP2005500298A (enExample)
KR (1) KR20040010744A (enExample)
CN (1) CN1527711A (enExample)
AR (1) AR034493A1 (enExample)
AT (1) ATE286397T1 (enExample)
AU (1) AU2002323873B2 (enExample)
BR (1) BR0211008A (enExample)
CA (1) CA2450787C (enExample)
CZ (1) CZ299951B6 (enExample)
DE (2) DE10129265A1 (enExample)
EA (1) EA006647B1 (enExample)
ES (1) ES2236551T3 (enExample)
HU (1) HUP0400865A3 (enExample)
IL (2) IL159345A0 (enExample)
MX (1) MXPA03011825A (enExample)
MY (1) MY129726A (enExample)
NO (1) NO20035458D0 (enExample)
NZ (1) NZ529944A (enExample)
PL (1) PL367207A1 (enExample)
PT (1) PT1397138E (enExample)
SK (1) SK287180B6 (enExample)
TW (1) TWI325320B (enExample)
UA (1) UA76753C2 (enExample)
WO (1) WO2002102388A2 (enExample)
ZA (1) ZA200309232B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10134038A1 (de) * 2001-07-12 2003-02-06 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Therapie der Nikotinabhängigkeit
DE10318714B4 (de) * 2003-04-25 2006-03-23 Hf Arzneimittelforschung Gmbh Wirkstoff-Kombinationen und Therapien zur Bekämpfung des Alkoholmissbrauches
DE10354894A1 (de) * 2003-11-24 2005-07-07 Hf Arzneimittelforschung Gmbh Orale Formulierungen des Desoxypeganins und deren Anwendungen
DE102004048927A1 (de) * 2004-10-06 2006-04-20 Lts Lohmann Therapie-Systeme Ag Pharmazeutische Kombination enthaltend Desoxypeganin und Cyp2D6 Inhibitoren
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
EP1874282B1 (en) 2005-04-06 2010-09-15 Adamas Pharmaceuticals, Inc. Methods and compositions for treatment of cns disorders
WO2006124585A2 (en) * 2005-05-13 2006-11-23 Alza Corporation Multilayer drug system for the delivery of galantamine
WO2007026841A1 (ja) 2005-09-01 2007-03-08 Mitsubishi Chemical Corporation ポリエステル粒子の熱処理装置及びポリエステル粒子の多段固相重縮合方法
EP1937226A2 (en) * 2005-09-23 2008-07-02 Alza Corporation Transdermal galantamine delivery system
ES2530047T3 (es) 2009-02-12 2015-02-26 Indiana University Research And Technology Corporation Material y métodos para el tratamiento de trastornos del desarrollo que incluyen autismo idiopático y comórbido
BR112012013487A2 (pt) 2009-12-02 2017-10-03 Adamas Pharmaceuticals Inc Composições de amantadina e métodos de uso
CA2850468C (en) 2010-09-28 2019-08-13 Depomed, Inc. Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
AU2011336304B2 (en) * 2010-12-03 2017-03-30 Nalpropion Pharmaceuticals Llc Increasing drug bioavailability in naltrexone therapy
WO2013160728A1 (en) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
US10493045B2 (en) * 2016-12-14 2019-12-03 Ru-Band Lu Method for treating alcohol dependence or alcohol abuse
IL272834B2 (en) 2017-08-24 2024-08-01 Adamas Pharma Llc Amantadine compositions, preparations thereof, and methods of use
BG67408B1 (bg) * 2019-04-12 2022-01-17 Софарма Ад Перорален лекарствен състав с растителен алкалоид, за лечение на зависимости

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3996934A (en) * 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US3742951A (en) * 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US4031894A (en) * 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
DE3315272C2 (de) * 1983-04-27 1986-03-27 Lohmann Gmbh & Co Kg, 5450 Neuwied Pharmazeutisches Produkt und Verfahren zu seiner Herstellung
DE3843239C1 (enExample) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
EP0424179A3 (en) * 1989-10-20 1991-12-27 John William Olney Use of combined excitatory amino acid and cholinergic antagonists to prevent neurological deterioration
DE4010079A1 (de) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
US5519017A (en) * 1990-03-29 1996-05-21 Lts Lohmann Therapie-Systeme Gmbh + Co. Kg Pharmaceutic formulation for the treatment of alcoholism
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
PL184590B1 (pl) * 1994-10-21 2002-11-29 Sanochemia Pharmazeutika Ag Sposób wytwarzania pochodnych a heksahydro H benzofuro[ a ef][ ] benzoazepiny sposób odbromowania tych pochodnych sposób wytwarzania związków typu N demetylobromo i epibromo galantaminy oraz nowe związki z określonego zbioru
DE19509663A1 (de) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
GB9514821D0 (en) * 1995-07-19 1995-09-20 Sod Conseils Rech Applic Galanthamine derivatives
AT403803B (de) * 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
EP0945133A1 (en) * 1998-03-26 1999-09-29 Lipha Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator
EP1071655A1 (en) * 1998-04-17 2001-01-31 Kenneth Curry Cubane derivatives as metabotropic glutamate receptor antagonists and process for their preparation
DE19906978B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Pharmazeutische Zusammensetzung enthaltend Desoxypeganin zur Behandlung der Drogenabhängigkeit
DE19906974C2 (de) * 1999-02-19 2003-10-09 Lohmann Therapie Syst Lts Verwendung von Desoxypeganin zur Behandlung des Alkoholismus
DE19906979B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Verwendung von Desoxypeganin zur Behandlung der Nikotinabhängigkeit

Also Published As

Publication number Publication date
ES2236551T3 (es) 2005-07-16
CA2450787C (en) 2009-06-02
EP1397138A2 (de) 2004-03-17
SK287180B6 (sk) 2010-02-08
US20040192683A1 (en) 2004-09-30
AU2002323873B2 (en) 2006-11-16
IL159345A0 (en) 2004-06-01
ATE286397T1 (de) 2005-01-15
IL159345A (en) 2009-02-11
CN1527711A (zh) 2004-09-08
AR034493A1 (es) 2004-02-25
PL367207A1 (en) 2005-02-21
NZ529944A (en) 2007-02-23
JP2005500298A (ja) 2005-01-06
PT1397138E (pt) 2005-04-29
TWI325320B (en) 2010-06-01
DE50201958D1 (de) 2005-02-10
EA006647B1 (ru) 2006-02-24
HUP0400865A3 (en) 2011-03-28
CZ20033390A3 (en) 2004-03-17
EA200400041A1 (ru) 2004-04-29
CZ299951B6 (cs) 2009-01-07
BR0211008A (pt) 2004-10-26
UA76753C2 (uk) 2006-09-15
MY129726A (en) 2007-04-30
HUP0400865A2 (hu) 2004-07-28
CA2450787A1 (en) 2002-12-27
HK1063292A1 (en) 2004-12-24
WO2002102388A2 (de) 2002-12-27
KR20040010744A (ko) 2004-01-31
SK15652003A3 (sk) 2004-04-06
NO20035458D0 (no) 2003-12-08
WO2002102388A3 (de) 2003-09-18
EP1397138B1 (de) 2005-01-05
DE10129265A1 (de) 2003-01-02
ZA200309232B (en) 2004-07-21

Similar Documents

Publication Publication Date Title
MXPA03011825A (es) Combinacion de ingrediente activo para tratar una dependencia de sustancias aditivas o narcoticas utilizando medicamentos.
PT1202724E (pt) Metodo para tratamento da dor cronica utilizando inibidores mek
ES2138271T3 (es) Compuestos de 6-dimetil-amino-metil-1-fenil-ciclohexano como principio activo farmaceutico.
WO2002051470A3 (en) Injection systems
AU2001255467A1 (en) Security systems for delivering goods and services
DK0703786T3 (da) Anvendelse af nona- og dekapeptider til fremstilling af et lægemiddel til behandling af AIDS
ZA200110173B (en) Safety syringe.
AU2003213425A1 (en) Vaporizer, various devices using the same, and vaporizing method
AP1703A (en) Heparin-derived polysaccharide mixtures, preparation method and pharmaceutical compositions containing same.
HUT70705A (en) Device for vaporizing an active substance, for example insecticide or airfresheuer
AU5170499A (en) Use of ginkgo biloba extracts for preparing a medicine for treating amyotrophic lateral sclerosis
WO2001055409A3 (en) Microbes and methods for remediation
BR9608255A (pt) Sistema terapéutico transdérmico (stt) para a administração de testosterona
ZA200304928B (en) Medicament containing a polyamine as an active substance.
NZ525774A (en) Use of SARP-1 for the treatment and/or prevention of scleroderma
WO2001085165A3 (de) Kombination von liponsäure und c1-donoren zur behandlung von störungen des zentralen nervensystems
ZA9710242B (en) Substituted Nitrogen Heterocycles, processes for their preparation and their use as pesticides.
EP1273301A3 (en) Pharmaceutical preparations based on active ingredients susceptible to illict administration
AU2001295979A1 (en) Medicinal compositions, dose and method for treating malaria
ZA963744B (en) Topical aciclovir preparation
EP1018336A4 (en) carcinostatic
IT1290910B1 (it) 2-amminotetralina otticamente attiva, procedimento per la sua preparazione e composizioni farmaceutiche che la contengono, attive
IL139303A0 (en) Treatment of arthritis and other similar conditions
CA2452432A1 (en) Active ingredient combination for the pharmacological therapy of nicotine dependence
WO1999029319A3 (en) Chemical compounds for use as anxiolytic agents and a method for the identification of anxiolytic compounds

Legal Events

Date Code Title Description
FG Grant or registration